Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Leerink Swann upped their FY2018 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report released on Wednesday. Leerink Swann analyst P. Matteis now expects that the biopharmaceutical company will post earnings per share of ($5.02) for the year, up from their previous estimate of ($5.21). Leerink Swann has a “Market Perform” rating and a $72.00 price target on the stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same period last year, the firm posted ($1.05) earnings per share.

COPYRIGHT VIOLATION NOTICE: “FY2018 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By Leerink Swann (ALNY)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/fy2018-earnings-estimate-for-alnylam-pharmaceuticals-inc-issued-by-leerink-swann-alny/1586615.html.

Several other research firms also recently commented on ALNY. Chardan Capital reiterated a “buy” rating and issued a $124.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday. Stifel Nicolaus reiterated a “hold” rating and issued a $83.00 price objective (up from $56.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $116.00 price objective (up from $110.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Cowen and Company reiterated an “outperform” rating and issued a $117.00 price objective (up from $93.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Finally, Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, September 20th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $93.11.

In other news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.30% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 22.0% during the 2nd quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 2,093 shares in the last quarter. TLP Group LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $380,000. Wellington Management Group LLP lifted its position in shares of Alnylam Pharmaceuticals by 0.3% during the 1st quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares in the last quarter. Hemenway Trust Co LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $235,000. Finally, BlackRock Inc. lifted its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares in the last quarter. 94.25% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.